Clinical Trial Update: Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

This entry describes a Phase 1/2 clinical trial evaluating the safety and efficacy of Tremelimumab plus Durvalumab in combination with transarterial chemoemboli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Transarterial chemoembolization (chemotherapy with embolization (various agents))
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Yoon Jun Kim | Conditions: Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: RECRUITING